Old Web
English
Sign In
Acemap
>
authorDetail
>
Rosalin Arends
Rosalin Arends
Pfizer
Medicine
Pharmacokinetics
Tanezumab
Pharmacodynamics
Pharmacology
4
Papers
111
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Scientific strategies necessary to resolve FDA clinical hold on anti-nerve growth factor inhibitors: The story of tanezumab
2016
Journal of Toxicological Sciences
Patrice Belanger
Mark Butt
Paul Butler
Siddhartha Bhatt
Stephen Foote
Dave Shelton
Mark G. Evans
Rosalin Arends
Susan Hurst
Carlin Okerberg
Thomas Cummings
David M. Potter
Jill Steidl-Nichols
Mark Zorbas
Show All
Source
Cite
Save
Citations (0)
Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain.
2016
British Journal of Clinical Pharmacology
E. Niclas Jonsson
Rujia Xie
Scott Marshall
Rosalin Arends
Show All
Source
Cite
Save
Citations (12)
Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects.
2012
British Journal of Clinical Pharmacology
Gai Ling Li
Helen Winter
Rosalin Arends
Gary W. Jay
Vu Le
Tim Young
John P. Huggins
Show All
Source
Cite
Save
Citations (97)
Preliminary Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis for the Effect of Tanezumab on Overall Daily Pain Score Data in Adults with Moderate-to-Severe Pain due to Osteoarthritis of the Knee
2009
Rujia Xie
Rosalin Arends
Stephen Olson
Scott Marshall
Show All
Source
Cite
Save
Citations (2)
1